Abstract
The cornea is the clear window at the front of the eye and is the eye's main refractive medium. Its transparency is essential for vision. Corneal neovascularisation is a common clinical problem with serious consequences for vision; it can compromise corneal transparency and plays a major role in corneal graft rejection by breaching corneal immune privilege. In this review, we formulate a consensus on the unmet medical needs in the management of corneal neovascularisation and outline a framework for the clinical research that is needed to identify suitable agents to meet these needs.
| Original language | English |
|---|---|
| Pages (from-to) | 3-9 |
| Number of pages | 7 |
| Journal | British Journal of Ophthalmology |
| Volume | 96 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2012 |
Keywords
- Angiogenesis Inhibitors/therapeutic use
- Corneal Diseases/drug therapy
- Corneal Neovascularization/drug therapy
- Humans
- Ophthalmology/standards
- Practice Guidelines as Topic
Fingerprint
Dive into the research topics of 'Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation: outcome of an expert roundtable'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver